Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk

• Main Authors: Naila Goldenberg, Charles Glueck
• Format: Article
• Language: English
• Published: Dove Medical Press 2009-04-01
• Series: Vascular Health and Risk Management
• Online Access: http://www.dovepress.com/efficacy-effectiveness-and-real-life-goal-attainment-of-statins-in-man-a3080

Naila Goldenberg1,2, Charles Glueck11Cholesterol and Metabolism Center of Jewish Hospital, Cincinnati, Ohio, USA; 2University of Cincinnati, Division of Endocrinology and Metabolism, Cincinnati, Ohio, USAAbstract: Statins became available for the treatment of hypercholesterolemia in 1987. Multiple, well-designed, placebo-controlled, double-blind studies revealed that each 1% reduction in serum cholesterol level was associated with about 1% reduction in risk of cardiovascular events. Low-density lipoprotein (LDL) cholesterol reduction to less than 78 mg/dL may be associated with reduction of atheroma burden. Patients with high levels of high specificity C-reactive protein and having LDL cholesterol less than 3.4 mmol/L (130 mg/dL) in primary prevention settings benefited from aggressive LDL cholesterol reduction with rosuvastatin over a 2-year period. However, in real life practice, about half of patients who are prescribed statins discontinue the medication by the end of the year. Medication adherence is lower in younger patients, women, and absence of known coronary heart disease. Personal features of the prescribing physician and dispensing pharmacies also affect patients’ compliance. More studies are needed to evaluate if “compliance packets” would benefit patients in a real life situation.Keywords: cardiovascular risk, statin, goal attainment, primary prevention, secondary prevention